Forty Seven Inc (FTSV) Stock News
NASDAQ:FTSV - Nasdaq -
FTSV Latest News, Press Relases and Analysis
Gilead, Biogen Lead Biotechs That ‘Need to Do Deals’ for Growth
Biotech mergers should pick up steam this year as cash-rich companies whose shares stumbled through 2020 -- like Amgen Inc. and Gilead Sciences Inc. -- look to replenish wavering pipelines.
Cancer Drug Bet Pays Off for Biotech CEO With 3,600% Stock Surge
When Jan Skvarka joined biotechnology firm Trillium Therapeutics Inc. as chief executive officer, he made a big bet to reshape the company and went all-in on a cancer treatment platform. Now, he’s reaping the rewards.
Orca Bio Emerges as $1 Billion-Plus Biotech With Mystery Backer
Orca Bio raised $192 million from Lightspeed Venture Partners and an unnamed investor for its experimental cell therapy platform.
Why Forty Seven Stock Skyrocketed 64.5% in March
Word of the biotech's pending acquisition pushed its stock to a record high.
Mentions: GILD
Gilead Analyst Sees Over 50% Chance Of Success For Remdesivir In Mild-To-Moderate COVID-19
The world is waiting with baited breath for the outcome of two late-stage studies underway in China for Gilead Sciences, Inc.'s (NASDAQ: GILD) remdesivir as a potential...
Mentions: GILD
Gilead completes Forty Seven buy (NASDAQ:GILD)
Gilead Sciences (NASDAQ:GILD) has finalized its $4.9B acquisition of Forty Seven (NASDAQ:FTSV) announced in early March.FTSV's lead candidate is magrolimab, a CD47-targeting monoclonal antibody in Pha
Mentions: GILD
Gilead competes Forty Seven buy (NASDAQ:GILD)
Gilead Sciences (NASDAQ:GILD) has finalized its $4.9B acquisition of Forty Seven (NASDAQ:FTSV) announced in early March.
Mentions: GILD
The Daily Biotech Pulse: Sanofi, Regeneron Finalize Praluent Restructuring, Natus Pre-Announces Q1 Shortfall, Alcon To Delay Dividend Initiation
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs April 6.) Forty Seven Inc (NASDAQ:...
Gilead Sciences Pins Its Hopes on Remdesivir
Clinical trial results for Gilead's remdesivir should come this month. If it's effective, GILD stock could explode higher on the news.
Mentions: GILD
Best & Worst Performing Mid Cap Stocks for April 6, 2020
IMMU – IMMU leads the way today as the best performing mid cap stock, closing up 99.79%.
Should You Buy Forty Seven Before Gilead Sciences' Acquisition Closes?
The immuno-oncology buyout is set to close this quarter.
Mentions: GILD
Gilead Sciences’ Coronavirus Treatment Has Big-Time Potential
Gilead Sciences is working on a coronavirus treatment, while GILD stock works on a breakout. Let's examine it more closely.
Demand for Essential Goods Rises Amid Coronavirus: 3 Winners
Despite the lagging markets, companies that offer pharmaceuticals and FMCG products have witnessed a surge in recent weeks, largely driven by strong demand for their goods.
GILD Stock Remains a Smart Play Now and in the Future
Gilead Science’s clinical trial for remdesivir continues. With or without it, GILD stock remains a smart play.
Mentions: GILD
Gilead’s Cash and the Coronavirus Make GILD Stock Look Cheap
Gilead Sciences rose to prominence with its hepatitis C drug. Now GILD stock is soaring on hopes for a coronavirus treatment.
Mentions: GILD
Top Ranked Momentum Stocks to Buy for March 30th
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, March 30th
Gilead nearing finish line on Forty Seven buy
Gilead Sciences (NASDAQ:GILD) announces the expiration of the HSR waiting period regarding its previously announced acquisition of Forty Seven (NASDAQ:FTSV) for ~$4.9B. The transaction should close in
Mentions: GILD
Stop Chasing Coronavirus Plays Like Moderna Stock
Stocks like MRNA stock have soared on hopes they will benefit from the coronavirus pandemic. But history shows few, if any, actually will.
Coronavirus Scare Supports These Biotech ETFs & Stocks
Growing coronavirus concerns provide some support to these biotech ETFs and stocks amid a massive market sell-off.
Forty Seven EPS beats by $0.10
Forty Seven (NASDAQ:FTSV): Q4 GAAP EPS of -$0.61 beats by $0.10.Cash, equivalents and short-term investments of $329.09M (+136.7% Y/Y)Press Release
Remdesivir, Other Positive Catalysts Should Lift Gilead Stock
Remdesivir appears to have helped coronavirus patients, and the drug looks poised to boost GILD stock in the medium term.
Mentions: GILD
FORTY SEVEN ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of FTSV and Encourages Investors to Contact the Firm
Best & Worst Performing Mid Cap Stocks for March 16, 2020
BNTX – BNTX leads the way today as the best performing mid cap stock, closing up 29.32%.
4 Big Drug/Biotech Stocks Up in Coronavirus-Hit Economy
Here we highlight four bigshot drugmakers/biotechs whose stocks are up this year in spite of the coronavirus impact.